Radotinib - Il-Yang
Alternative Names: IY-5511; IY5511HCl; Radotinib hydrochloride; SupectLatest Information Update: 18 Jun 2024
At a glance
- Originator Il-Yang
- Class Antineoplastics; Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors; Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia
- Phase II Parkinson's disease
Most Recent Events
- 14 Jun 2024 Il-Yang plans a phase I pharmacokinetics trial (In volunteers) in South Korea (PO) (NCT06461078)
- 21 Feb 2022 Phase-II clinical trials in Parkinson's disease (In adults) in France (PO) (NCT04691661)
- 31 Dec 2020 Il-Yang plans a phase II trial for Parkinson's disease in France (PO) in January 2021 (NCT04691661)